We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We found a consistent, significant benefit across the full range of EF, including HF with reduced EF, HF with midrange EF and HFpEF, each showing a consistent benefit.”
“Patients treated with sotagliflozin in the SOLOIST-WHF trial experienced fewer single as well as multiple heart failure events than those receiving placebo. Thus, we conclude that sotagliflozin altered the trajectory of patients hospitalized for worsening heart failure by reducing early and recurrent heart failure events.”
“Sotagliflozin adds to the SGLT2 inhibitor story, and the SOLOIST-WHF results may shift our focus to vulnerable, acute heart failure patients with an opportunity to treat during the transition phase.”
No takes yet. Share an insight, caveat, or question.
Zitelny et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: